Abstract
PTEN is a putative tumour suppressor gene located on chromosome band 10q23. Mutations in PTEN have been identified in numerous human malignancies, including cancers of the brain, endometrium, ovary, and prostate. In this study, we screened 80 Barrett’s oesophagus-associated adenocarcinomas (BOAd) for loss of heterozygosity (LOH) at 10q23, using the microsatellite markers D10S541, D10S219, and D10S551. Tumours demonstrating LOH were then screened for the presence or absence of PTEN mutations. LOH at one or more loci was identified in 17/80 (21%) cases. In none of these cases did we detect mutations in PTEN. The presence of LOH did not correlate with patient age, tumour stage, degree of differentiation, presence of perineural or vascular invasion, or overall survival. We conclude that LOH at chromosome 10q23 is uncommon in BOAd, is not associated with mutations in the PTEN tumour suppressor gene, and does not correlate with the clinical or pathologic features of these tumours. It is possible that PTEN is inactivated through other mechanisms in BOAd. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alimov A, Li C, Gizatullin R, Fredriksson V, Sundelin B, Klein G and Zabarovsky E (1999) Somatic mutation and homozygous deletion of PTEN/MMAC1 gene at 10q23 in renal cell carcinoma. Anticancer Res 19: 3841–3846
Aveyard J, Skilleter A, Habuchi T and Knowles M (1999) Somatic mutations of PTEN in bladder carcinoma. Br J Cancer 80: 904–908
Blot W, Devesa S, Kneller R and Fraumeni J (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287–1289
Bose S, Wang S, Terry M, Hibshoosh H and Parsons R (1998) Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17: 123–127
Bostrom J, Cobbers J, Wolter M, Tabatabai G, Weber R, Lichter P, Collins V and Reifenberger G (1998) Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58: 29–33
Boynton R, Blount P, Yin J, Brown V, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau J, Raskind W, Haggitt R, Reid B and Meltzer S (1992) Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA 89: 3385–3388
Butler M, Wang S, Chaganti R, Parsons R and Dalla-Favera R (1999) Analysis of PTEN mutations and deletions in B-cell non-hodgkins lymphomas. Genes Chromosomes Cancer 24: 322–327
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman J, Jen Isaacs W, Bova G and Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res,
Cairns P, Evron E, Okami K, Halamachi N, Esteller M, Herman J, Bose S, Wang S, Parsons R and Sidransky D (1998) Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16: 3215–3218
Chen S, Yu S, Tsai M, Yeh K, Wang J, Kao M, Shih M and Chang J (1999) Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer. Breast Cancer Res Treat 55: 85–89
Chiariello E, Roz L, Albarosa R, Magnani I and Finocchiaro G (1998) PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 16: 541–545
Dahia P, Marsh D, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C and Eng C (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57: 4710–4713
Dahia P, Aguiar R, Alberta J, Kum J, Caron S, Sill H, Marsh D, Ritz J, Freedman A, Stiles C and Eng C (1999) PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 8: 185–193
Davies M, Gibbs F, Halliwell N, Joyce K, Roebuck M, Rossi M, Salisbury J, Sibson D, Tacconi L and Walker C (1999) Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br J Cancer 79: 1542–1548
Dolan K, Grade J, Gosney J, Sissons M, Wright T, Kingsnorth A, Walker S, Sutton R, Meltzer S and Field J (1998) Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 78: 950–957
Dong J, Sipe T, Hyytinen E, Li C, Heise C, McClintlock D, Grant C, Chung L and Frierson H (1998) PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17: 1979–1982
Duerr E, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz M, Louis D, Schramm J, Wiestler O, Parsons R, Eng C and Deimling A (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16: 2259–2264
Esposito V, Baldi A, DeLuca A, Groger A, Loda M, Giordano G, Caputi M, Baldi F, Pagano M and Giordano A (1997) Prognostic role of the cyclin-dependent kinase inhibitor in non-small cell lung cancer. Cancer Res 57: 3381–3385
Feilotter H, Nagai M, Boag A, Eng C and Mulligan L (1998) Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743–1748
Feilotter H, Coulon V, McVeigh J, Goag A, Dorion-Bonnet F, Duboue B, Latham W, Eng C, Mulligan L and Longy M (1999) Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79: 718–723
Flejou J, Paraf F and Potet F (1994) p53 protein expression in Barrett’s adenocarcinoma: a frequent event with no prognostic significance. Histopathology 24: 487–489
Fleming I, Cooper J and Henson D (1997). AJCC manual for staging of cancer, 5th ed. Berlin, New York, Wiley
Freihoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler O, Deimling A and Schmutzler R (1999) Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 79: 754–758
Garcia J, Silva J, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P and Bonilla F (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57: 237–243
Gasparotto D, Vukosavljevic T, Piccinin S, Barzan L, Sulfaro S, Armellin M, Boiocchi M and Maestro R (1999) Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer 84: 432–436
Gimm O, Perren A, Weng L, Marsh D, Yeh J, Ziebold U, Gil E, Hinze R, Delbridge L, Lees J, Robinson B, Komminoth P, Dralle H and Eng C (2000) Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156: 1693–1700
Gleeson C, Sloan J and McGuigan J (1995) Base transitions at CpG nucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 55: 3406–3411
Gonzalez M, Artimez M, Rodrigo L, Lopez-Larrea C, Menendez M, Alvarez V, Perez R, Fresno M, Perez M, Sampedro A and Coto E (1997) Mutation analysis of the p53, APC, and p16 genes in the Barrett’s oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 50: 212–217
Gray I, Stewart L, Phillips S, Hamilton J, Gray N, Watson G, Spurr N and Snary D (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78: 1296–1300
Gronbaek Y, Zeuthen J, Guldberg P, Ralfkiaer E and Hou-Jensen K (1998) Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood 91: 4388–4390
Guldberg P, Straten P, Birck A, Ahrenkiel V, Kirkin A and Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent even in malignant melanoma. Cancer Res 57: 3660–3663
Hamelin R, Flejou J and Muzeau F (1994) TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett’s esophagus. Gastroenterology 107: 1012–1018
Hammoud Z, Kaleem Z, Cooper J, Sundaresan R, Patterson G and Goodfellow P (1996) Allelotype analysis of esophageal adenocarcinomas: evidence for involvement of sequences on the long arm of chromosome 4. Cancer Res 56: 4499–4502
Huang Y, Boynton R, Blount P, Silverstein R, Yin J, Tong Y, McDaniel T, Newkirk C, Resau J, Sridhara R, Reid B and Meltzer S (1992) Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 52: 6525–6530
Kohno T, Takahashi M, Manda R and Yokota J (1998) Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chrom Cancer 22: 152–156
Kong D, Suzuki A, Zou T, Sakurada A, Kemp L, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham J, Souza R, Smolinski K, Meltzer S and Horii A (1997) PTEN1 is frequently mutated in primary endometrial carcinomas. Nature Genet 17: 143–144
Kurose K, Zhou X, Araki T and Eng C (2000) Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. Gene Chrom Cancer 29: 166–172
Lagergren J, Bergstrom R, Lindgren A and Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825–831
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, MCombie R, Bigner S, Giovanella B, Ittman M, Tycko B, Hibshoosh H, Wigler M and Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275,
Liaw D, Marsh D, Li J, Dahia P, Wang S, Zheng Z, Bose S, Call K, Tsou H, Peacocke M, Eng C and Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64–67
Liggett W and Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197–1206
Liu W, James D, Frederick L, Alderete B and Jenkins R (1997) PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57: 5254–5257
Maier D, Zhang Z, Taylor E, Hamou M, Gratzl O, Meir E, Scott R and Merlo A (1998) Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25–26 region as the primary target in low-grade and high-grade gliomas. Oncogene 16: 5551–5555
Marsh D, Dahia P, Zheng Z, Liaw D, Parsons R, Gorlin R and Eng C (1997a) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genet 16: 333–334
Marsh D, Roth S, Lunetta K, Hemminki A, Dahia P, Sistonen P, Zheng Z, Caron S, Orsouw Nv, Bodmer W, Cottrell S, Dunlop M, Eccles D, Hodgson S, Jarvinen H, Kellokumpu I, Markie D, Neale K, Phillips R, Rozen P, Syngal S, Vijg J, Tomlinson I, Aaltonen L and Eng C (1997b) Exclusion of PTEN and 10q22–24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res 57: 5017–5021
Marsh D, Dahia P, Caron S, Kum J, Fralyling I, Tomlinson I, Hughes K, Eeles R, Hodgson S, Murday V, Houlston R and Eng C (1998) Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 35: 881–885
Marsh D, Kum J, Lunetta K, Bennett M, Gorlin R, Ahmed S, Bodurtha J, Crowe C, Curtis M, Dasouki M, Dunn T, Feit H, Geraghty M, Graham J, Hodgson S, Hunter A, Korf B, Manchester D, Miesfeldt S, Murday V, Nathanson K, Parisi M, Pober B, Romano C, Tolmie J, Trembath R, Winter R, Zackai E, Zori R, Weng L, Dahia P and Eng C (1999) PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Molec Genet 8: 1461–1472
McMenamin M, Soung P, Perera S, Kaplan I, Loda M and Sellers W (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291–4296
Mutter G, Lin M, Fitzgerald J, Kurn J, Baak J, Lees J, Weng L and Eng C (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924–931
Muzeau F, Flejou J, Thomas T and Hamelin R (1997) Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. Int J Cancer 72: 27–30
Myers M, Stolarov J, Eng C, Li J, Wang S, Wigler M, Parsons R and Tonks N (1997) PTEN, the tumor suppressor from human chromosome 10q23, is a dual specificity phosphatase. Proc Natl Acad Sci (USA) 94: 9052–9057
Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate T and Saito H (1998) Mutational analysis of the PTEN/MMAC1 gene in non-hodgkin’s lymphoma. Leukemia 12: 1277–1280
Neshat K, Sanchez C and Galipeau P (1994) p53 mutations in Barrett’s adenocarcinoma and high grade dysplasia. Gastroenterology 106: 1589–1595
Obata K, Morland S, Watson R, Hitchcock A, Chenevix-Trench G, Thomas E and Campbell I (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res, 2095–2097
Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, Halachmi N, Ahrendt S, Reed A, Hilgers W, Kern S, Koch W, Sidransky D and Jen J (1998) Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res, 509–511
Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C and Lidereau R (1998) PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16: 2879–2883
Petersen S, Rudolf J, Bockmuhl U, Gellert K, Wolf G, Dietel M and Petersen I (1998). Distinct regions of allelic imbalance on chromosome 10q22–q26 in squamous cell carcinomas of the lung,
Rasheed B, Stenzel T, McLendon R, Parsons R, Friedman A, Friedman H, Bigner D and Bigner S (1997) PTEN gene mutations are seen in high grade but not in low grade gliomas. Cancer Res 57: 4187–4190
Risinger J, Hayes A, Berchuk A and Barrett J (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736–4738
Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J and Tanaka T (2000) Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 85: 160–165
Sakai A, Thieblemont C, Wellmann A, Jaffe E and Raffeld M (1998) PTEN gene alterations in lymphoid neoplasms. Blood 92: 3410–3415
Schneider P, Casson A, Levin B, Garewal H, Hoelscher A, Becker K, Dittler H, Cleary K, Troster M, Siewert J and Roth J (1996) Mutations of p53 in Barrett’s esophagus and Barrett’s cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 111: 323–333
Shao X, Tandon R, Samara G, Kanki H, Yano H, Close L, Parsons R and Sato T (1998) Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int J Cancer 77: 684–688
Simpkins S, Peiffer-Schneider S, Mutch D, Gersell D and Goodfellow P (1998) PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol 71: 391–395
Singh B, Ittmann M and Krolewski J (1998a) Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 21: 166–171
Singh S, Lipman J, Goldman H, Ellis F, Aizenman L, Cangi M, Signoretti S, Chiaur D, Pagano M and Loda M (1998b) Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma. Cancer Res 58: 1730–1735
Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A, Langford L, Baumgard M, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng D and Tavtigian S (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15: 356–362
Suzuki H, Freije D, Nusskern D, Okami K, Cairns P, Sidransky D, Isaacs W and bova G (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58: 204–209
Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M and Loda M (1997) The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 57: 1259–1263
Tashiro H, Blazes M, Wu R, Cho K, Bose S, Wang S, Li J, Parsons R and Ellenson L (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935–3940
Teng D, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen K, Vinson V, Gumpper K, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford L, Lee J, Mills G, Pershouse M, Pollack R, Tornos C, Troncoso P, Yung W, Fujii G, Berson A, Bookstein R, Bolen J, Tavtigian S and Steck P (1997) MMAC1/PTEN mutations in primary tumor specimens and cell lines. Cancer Res 57: 5221–5225
Tsao H, Zhang X, Benoit E and Haluska F (1998) Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16: 3397–3402
Vijeyasingam R, Darnton S, Jenner K, Allen C, Billingham C and Matthews H (1994) Expression of p53 protein in oesophageal carcinoma: clinicopathological correlation and prognostic significance. Br J Surg 81: 1623–1626
Wang S, Puc J, Li J, Bruce J, Cairns P, Sidransky D and Parsons R (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57: 4183–4186
Whang Y, Wu X, Suzuki H, Reiter R, Tran C, Vessalla R, Said J, Isaacs W and Sawyers C (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. PNAS 95: 5246–5250
Yaginuma Y, Yamashita T, Ishiya T, Morizaki A, Katoh Y, Takahashi T, Hayashi H and Ishikawa M (2000) Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Molecular Caricinogenesis 27: 110–116
Yang R, Naitoh J, Murphy M, Wang H, Phillipson J, deKernion J, Loda M and Reiter R (1998) Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941–945
Yeh J, Marsh D, Zedenius J, Dwight T, Delbridge L, Robinson B and Eng C (1999) Fine-structure deletion mapping of 10q22–24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. Genes Chromosomes Cancer,
Yokomizo A, Tindall D, Drabkin H, Gemmill R, Franklin W, Yang P, Sugio K, Smith D and Liu W (1998) PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17: 475–479
Zhou X, Tarmin L, Yin J, Jiang H, Suzuki H, Rhyu M, Abraham J and Meltzer S (1994) The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9: 3737–3741
Zhou X, Li Y, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, Sanson M, Delattre J, Thomas G and Hamelin R (1999) Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 84: 150–154
Zhou X, Gimm O, Hampel H, Niemann T, Walker M and Eng C (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157: 1123–1128
Zhuang Z, Vortmeyer A, Mark E, Odze R, Emmert-Buck M, Merino M, Moon H, Liotta L and Duray P (1996) Barrett’s esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res 56: 1961–1964
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kulke, M., Odze, R., Thakore, K. et al. Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett’s oesophagus-associated adenocarcinoma. Br J Cancer 84, 748–753 (2001). https://doi.org/10.1054/bjoc.2000.1660
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1660
Keywords
This article is cited by
-
Assessment of Mutational Load in Biopsy Tissue Provides Additional Information About Genomic Instability to Histological Classifications of Barrett's Esophagus
Journal of Gastrointestinal Cancer (2014)
-
Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences
BMC Cancer (2009)
-
Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study
BMC Cancer (2007)